Dr Reddys launches generic version of Sensipar tablets in US

Dr. Reddy's Cinacalcet Tablets are available in 30 mg, 60 mg, and 90 mg tablets in a bottle count size of 30.

Published On 2020-10-03 08:00 GMT   |   Update On 2020-10-03 08:05 GMT
Advertisement

Hyderabad & Princeton: Drugmaker, Dr. Reddy's Laboratories Ltd., has recently announced the launch of Cinacalcet Tablets, a therapeutic equivalent generic version of Sensipar (cinacalcet) Tablets, approved by the U.S. Food and Drug Administration (USFDA).

Cinacalcet tablet is a positive modulator of the calcium sensing receptor indicated for:

• Secondary Hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on dialysis.

Advertisement

• Hypercalcemia in adult patients with Parathyroid Carcinoma (PC). 

• Severe hypercalcemia in adult patients with primary HPT who are unable to undergo parathyroidectomy. 

Dr. Reddy's Cinacalcet Tablets are available in 30 mg, 60 mg, and 90 mg tablets in a bottle count size of 30.

The Sensipar brand and generic market had U.S. sales of approximately $312 million MAT for the most recent twelve months ending in July 2020 according to IQVIA Health*.

Sensipar is a trademark of Amgen Inc.

Dr. Reddy's Laboratories Ltd. is an integrated pharmaceutical company headquartered in Hyderabad, committed to providing affordable and innovative medicines for healthier lives.

Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology.







Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News